Epilepsy Epidemiology Summary

Epilepsy Insights and Trends

• The overall prevalence of epilepsy is estimated at ~0.5–1.0% of the population (5–10 per 1,000 individuals), with a higher burden in low- and middle-income countries. 
• Focal epilepsy accounts for ~60% of cases, while generalized epilepsy represents ~20–30%, with remaining cases classified as unknown or mixed onset. 
• The incidence of epilepsy follows a bimodal age pattern, with peaks in early childhood and in adults aged ≥60 years, driven by genetic causes in younger populations and cerebrovascular disease in older adults.

Epilepsy Epidemiology Forecast in the 7MM

• 2025 Incident Cases of Epilepsy : ~XX
• Epilepsy Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Epilepsy Epidemiology Forecast 2036’ report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Epilepsy Understanding and Diagnosis Algorithm

Epilepsy Overview and Diagnosis

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal neuronal activity in the brain. It presents with transient disturbances in consciousness, motor, sensory, or behavioral function, depending on the region involved. Epilepsy is broadly classified into focal, generalized, and unknown onset seizures and arises from diverse etiologies, including genetic, structural, infectious, traumatic, and metabolic causes. Despite advances in anti-seizure therapies, a substantial proportion of patients continue to experience drug-resistant seizures, highlighting a significant unmet need.

Further details are provided in the report.....

Epilepsy Diagnosis

Diagnosis of Epilepsy is based on clinical history and seizure description, supported by EEG findings that detect abnormal brain electrical activity and help classify seizure type. Neuroimaging (MRI, CT, and PET) is used to identify structural or metabolic brain abnormalities underlying seizures. Blood tests help exclude metabolic, infectious, or genetic causes, while neurological and behavioral assessments evaluate disease impact and severity. Early and accurate diagnosis is critical for seizure classification and appropriate treatment initiation.

Further details are provided in the report.....

Epilepsy Epidemiology

Key Findings from Epilepsy Epidemiological Analysis and Forecast 

• According to epidemiological estimates, in 2025, the total number of individuals living with Epilepsy is approximately ~50–70 million worldwide, making it one of the most common chronic neurological disorders globally.
• The US had the highest cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.
• Focal epilepsy accounts for ~67% of all cases, while generalized epilepsy represents ~20–30%, with the remaining cases classified as unknown or combined onset types.
• Secondary epidemiological analyses highlight that incidence follows a bimodal age distribution, with peaks in early childhood and adults over 60 years, largely driven by genetic causes in pediatric patients and cerebrovascular disease in older adults.
• The prevalence of epilepsy is reported to be slightly higher in males than females in several population-based studies, although gender differences are generally modest and vary by region and underlying etiology.
• A significant proportion of epilepsy cases in low- and middle-income countries are associated with preventable causes such as perinatal injury, CNS infections, and traumatic brain injury, highlighting regional disparities in disease epidemiology.

Explore detailed Epilepsy market forecasts, emerging therapies, epidemiology insights, and competitive intelligence driving innovation and treatment advancements through 2036 within the 7MM countries.

Scope of the Report

• The report covers a segment of a descriptive overview of hand eczema, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Epilepsy Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of hand eczema? What will be the growth opportunities across the 7MM concerning the patient population with hand eczema?
• What is the historical and forecasted hand eczema patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.